Balaskas, Konstantinos
Glinton, S.
Keenan, T. D. L.
Faes, L.
Liefers, B.
Zhang, G.
Pontikos, N.
Struyven, R.
Wagner, S. K.
McKeown, A.
Patel, P. J.
Keane, P. A.
Fu, D. J.
Funding for this research was provided by:
Apellis Pharmaceuticals (KBALGA1)
Article History
Received: 22 June 2022
Accepted: 29 August 2022
First Online: 16 September 2022
Competing interests
: NP: Moorfields Eye Charity Career Development Award (R190031A), equity owner, Phenopolis Ltd. DJF: Consulting for Abbvie, Allergan, DeepMind. LF: Nothing to declare. GZ: No conflicts of interest. BL: No conflicts of interest. SG: Moorfields Eye Charity Grant (GR001003), Wellcome Trust Grant (206619_Z_17_Z). SKW: MRC Clinical Research Training Fellowship (MR/T000953/1). RS: No conflicts of interest. PAK: Moorfields Eye Charity Career Development Award (R190028A), UK Research & Innovation Future Leaders Fellowship (MR/T019050/1); Consulting for DeepMind, Roche, Novartis, Apellis and BitFount; equity owner in Big Picture Medical; speaker fees from Heidelberg Engineering, Topcon, Allergan, and Bayer. KB: Speaker fees from Novartis, Bayer, Alimera, Allergan and Heidelberg, consulting Novartis and Roche and research support from Apellis, Novartis and Bayer. PJP: Speaker fees from Bayer, Heidelberg, Roche and Topcon, consulting Bayer, Novartis, Oxford Bioelectronics and Roche and research support from Bayer. AM: Employee of Apellis. TK: No conflicts of interest.